VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMW 2021 | The evolution of MRD for myeloma

Lanny Kirsch, MD, Adaptive Biotechnologies, Seattle, WA, talks on how the use of measurable residual disease (MRD) has evolved in the past decade in the field of multiple myeloma, highlighting the advancement of techniques to measure MRD, such as flow cytometry and serum paraprotein analysis. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Lanny Kirsch, MD, is an employee and stock option holder in Adaptive Biotechnologies, Inc.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter